|
Symbol |
Name |
Market Cap |
Exchange |
Z-Score |
| XLRN | Acceleron Pharma Inc | $1.1B | NASDAQ | 29.3875 |
| ACRX | AcelRx Pharmaceuticals Inc | $113.3M | NASDAQ | -1.6859 |
| AKAO | Achaogen Inc | $815.5M | NASDAQ | 7.7258 |
| ACHN | Achillion Pharmaceuticals, Inc. | $529.0M | NASDAQ | 21.3633 |
| ACRS | Aclaris Therapeutics Inc | $572.1M | NASDAQ | 52.2689 |
| ACOR | Acorda Therapeutics Inc | $732.6M | NASDAQ | 0.8885 |
| ATNM | Actinium Pharmaceuticals Inc | $78.0M | NYSE MKT | 2.8273 |
| ADAP | Adaptimmune Therapeutics PLC - ADR | $278.1M | NASDAQ | 4.2211 |
| ADMA | ADMA Biologics Inc | $55.9M | NASDAQ | -4.1521 |
| ADRO | Aduro BioTech Inc | $641.0M | NASDAQ | 2.2078 |
| ADVM | Adverum Biotechnologies Inc | $126.1M | NASDAQ | 3.9134 |
| AGLE | Aeglea Bio Therapeutics Inc | $84.5M | NASDAQ | 12.6037 |
| AERI | Aerie Pharmaceuticals Inc | $1.3B | NASDAQ | 4.7423 |
| AFMD | Affimed NV | $73.2M | NASDAQ | 6.6478 |
| AGRX | Agile Therapeutics Inc | $100.9M | NASDAQ | -0.667 |
| AGIO | Agios Pharmaceuticals Inc | $2.0B | NASDAQ | 4.5919 |
| AKTX | Akari Therapeutics PLC (ADR) | $111.1M | NASDAQ | 4.2622 |
| AKBA | Akebia Therapeutics Inc | $493.1M | NASDAQ | 0.6219 |
| BIOD | Albireo Pharma Inc | $41.7M | NASDAQ | -1.3011 |
| ADHD | Alcobra Ltd | $32.2M | NASDAQ | 2.954 |
| ALDR | Alder Biopharmaceuticals Inc | $913.3M | NASDAQ | 20.5617 |
| ALDX | Aldeyra Therapeutics Inc | $49.2M | NASDAQ | 5.1389 |
| AMRN | Amarin Corporation plc (ADR) | $553.0M | NASDAQ | -6.9343 |
| AMGN | Amgen, Inc. | $118.0B | NASDAQ | 2.306 |
| AMPE | Ampio Pharmaceuticals Inc | $46.2M | NYSE MKT | -11.4887 |
| ANTH | Anthera Pharmaceuticals Inc | $21.4M | NASDAQ | -22.5204 |
| AGTC | Applied Genetic Technologies Corp | $104.8M | NASDAQ | 0.759 |
| APVO | Aptevo Therapeutics Inc | $41.9M | NASDAQ | 0.4489 |
| ARDM | Aradigm Corporation | $13.4M | NASDAQ | -23.2516 |
| ARDX | Ardelyx Inc | $353.1M | NASDAQ | 10.2376 |
| ARIA | Ariad Pharmaceuticals, Inc. | $4.7B | NASDAQ | 1.1281 |
| ARRY | Array Biopharma Inc | $949.8M | NASDAQ | -2.3484 |
| ARWR | Arrowhead Pharmaceuticals Inc | $126.8M | NASDAQ | -1.4104 |
| ASND | Ascendis Pharma A/S | $508.9M | NASDAQ | 28.9495 |
| ATRA | Atara Biotherapeutics Inc | $439.4M | NASDAQ | 26.0958 |
| ATHX | Athersys, Inc. | $166.9M | NASDAQ | -9.178 |
| BOLD | Audentes Therapeutics Inc | $374.4M | NASDAQ | 14.6877 |
| AUPH | Aurinia Pharmaceuticals Inc | $602.5M | NASDAQ | |
| EARS | Auris Medical Holding AG | $24.1M | NASDAQ | -2.9066 |
| AVEO | AVEO Pharmaceuticals, Inc. | $43.2M | NASDAQ | -25.0931 |
| AVXS | AveXis Inc | $1.8B | NASDAQ | 43.5059 |
| AVIR | Aviragen Therapeutics Inc | $19.3M | NASDAQ | -0.979 |
| AXSM | Axsome Therapeutics Inc | $79.5M | NASDAQ | 2.0882 |
| BGNE | Beigene Ltd (ADR) | $1.2B | NASDAQ | 14.0103 |
| BLPH | Bellerophon Therapeutics Inc | $51.8M | NASDAQ | -2.4065 |
| BLCM | Bellicum Pharmaceuticals Inc | $343.0M | NASDAQ | 4.1826 |
| ORPN | Bio Blast Pharma Ltd | $7.1M | NASDAQ | -2.0608 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $431.1M | NASDAQ | -5.4305 |
| BPMX | Biopharmx Corp | $31.4M | NYSE MKT | -3.6997 |
| APPY | Bioptix Inc | $17.7M | NASDAQ | -4.0192 |
| BSTC | BioSpecifics Technologies Corp. | $393.8M | NASDAQ | 30.151 |
| BSPM | Biostar Pharmaceuticals Inc | $4.7M | NASDAQ | 0.764 |
| BTX | BioTime, Inc. | $329.8M | NYSE MKT | 6.2858 |
| BLUE | bluebird bio Inc | $3.3B | NASDAQ | 7.8265 |
| CALA | Calithera Biosciences Inc | $385.3M | NASDAQ | 45.2195 |
| CAPR | Capricor Therapeutics Inc | $24.8M | NASDAQ | -2.3193 |
| CASC | Cascadian Therapeutics Inc (USA) | $83.5M | NASDAQ | -3.1972 |
| CATB | Catabasis Pharmaceuticals Inc | $30.3M | NASDAQ | -2.4482 |
| CPRX | Catalyst Pharmaceuticals Inc | $161.6M | NASDAQ | 37.8998 |
| CVM | CEL-SCI Corporation | $23.8M | NYSE MKT | -33.1222 |
| CELG | Celgene Corporation | $92.5B | NASDAQ | 3.8185 |
| CBMG | Cellular Biomedicine Group Inc | $75.7M | NASDAQ | 15.5781 |
| CLSN | Celsion Corporation | $13.3M | NASDAQ | -10.759 |
| CEMP | Cempra Inc | $1.3B | NASDAQ | 15.7976 |
| CERU | Cerulean Pharma Inc | $13.1M | NASDAQ | -6.4835 |
| CMRX | Chimerix Inc | $214.4M | NASDAQ | 11.1309 |
| CBPO | China Biologic Products Inc | $3.0B | NASDAQ | 14.6507 |
| CDTX | Cidara Therapeutics Inc | $122.6M | NASDAQ | 3.7748 |
| CLSD | Clearside Biomedical Inc | $184.7M | NASDAQ | 8.4733 |
| CLVS | Clovis Oncology Inc | $1.8B | NASDAQ | -0.6531 |
| CHRS | Coherus Biosciences Inc | $969.5M | NASDAQ | 1.2293 |
| CNAT | Conatus Pharmaceuticals Inc | $114.0M | NASDAQ | -0.8263 |
| CTRV | ContraVir Pharmaceuticals Inc | $45.3M | NASDAQ | -2.2018 |
| CRBP | Corbus Pharmaceuticals Holdings Inc | $280.0M | NASDAQ | 16.7986 |
| CYCCP | Cyclacel Pharmaceuticals Inc | $21.8M | NASDAQ | -20.5095 |
| CYCC | Cyclacel Pharmaceuticals Inc | $22.9M | NASDAQ | -20.3882 |
| CBAY | CymaBay Therapeutics Inc | $92.4M | NASDAQ | -26.4195 |
| CYNA | Cynapsus Therapeutics Inc | $504.0M | NASDAQ | |
| CYTK | Cytokinetics, Inc. | $571.7M | NASDAQ | 1.765 |
| CTMX | CytomX Therapeutics Inc | $530.5M | NASDAQ | 2.3915 |
| DERM | Dermira Inc | $952.4M | NASDAQ | 8.6677 |
| DMTX | Dimension Therapeutics Inc | $31.3M | NASDAQ | 0.0072 |
| DPRX | Dipexium Pharmaceuticals Inc | $13.9M | NASDAQ | -0.1264 |
| DRRX | DURECT Corporation | $167.7M | NASDAQ | -11.6296 |
| DVAX | Dynavax Technologies Corporation | $259.1M | NASDAQ | -1.9168 |
| EDGE | Edge Therapeutics Inc | $302.0M | NASDAQ | 8.1868 |
| EGLT | Egalet Corp | $76.4M | NASDAQ | -1.4667 |
| EBIO | Eleven Biotherapeutics Inc | $34.1M | NASDAQ | -0.8075 |
| ECYT | Endocyte, Inc. | $122.5M | NASDAQ | 10.232 |
| EPZM | Epizyme Inc | $947.6M | NASDAQ | 10.3551 |
| EXEL | Exelixis, Inc. | $5.0B | NASDAQ | 1.9582 |
| FATE | Fate Therapeutics Inc | $136.9M | NASDAQ | 2.1956 |
| FPRX | Five Prime Therapeutics Inc | $845.4M | NASDAQ | 10.0707 |
| FLKS | Flex Pharma Inc | $62.7M | NASDAQ | 9.0779 |
| FLXN | Flexion Therapeutics Inc | $613.3M | NASDAQ | 9.0874 |
| FOMX | Foamix Pharmaceuticals Ltd | $176.8M | NASDAQ | 19.023 |
| FWP | Forward Pharma A/S | $820.2M | NASDAQ | 78.8582 |
| GLMD | Galmed Pharmaceuticals Ltd | $53.7M | NASDAQ | 1.3587 |
| GEMP | Gemphire Therapeutics Inc | $92.6M | NASDAQ | 12.9492 |
| GERN | Geron Corporation | $456.7M | NASDAQ | 25.5684 |
| GILD | Gilead Sciences, Inc. | $86.5B | NASDAQ | 2.5557 |
| GLYC | GlycoMimetics Inc | $115.3M | NASDAQ | 6.7962 |
| GWPH | GW Pharmaceuticals PLC- ADR | $2.7B | NASDAQ | 29.5875 |
| HALO | Halozyme Therapeutics, Inc. | $1.8B | NASDAQ | 2.1197 |
| HTBX | Heat Biologics Inc | $19.1M | NASDAQ | 106.45 |
| HEB | Hemispherx BioPharma, Inc | $15.2M | NYSE MKT | -19.3144 |
| RXDX | Ignyta Inc | $277.0M | NASDAQ | 1.6642 |
| IMDZ | Immune Design Corp | $125.1M | NASDAQ | 2.7472 |
| IMMY | Imprimis Pharmaceuticals Inc | $49.5M | NASDAQ | -1.5823 |
| ITEK | Inotek Pharmaceuticals Corp | $44.4M | NASDAQ | -0.9863 |
| INSM | Insmed Incorporated | $1.1B | NASDAQ | 3.9544 |
| INSY | Insys Therapeutics Inc | $835.6M | NASDAQ | 7.0247 |
| NTEC | Intec Pharma Ltd | $59.2M | NASDAQ | |
| ICPT | Intercept Pharmaceuticals Inc | $2.9B | NASDAQ | 3.0524 |
| ITCI | Intra-Cellular Therapies Inc | $488.9M | NASDAQ | 21.9431 |
| JUNO | Juno Therapeutics Inc | $2.6B | NASDAQ | 5.4183 |
| KPTI | Karyopharm Therapeutics Inc | $350.5M | NASDAQ | 9.52 |
| KMPH | KemPharm Inc | $61.5M | NASDAQ | -0.6874 |
| KERX | Keryx Biopharmaceuticals | $692.6M | NASDAQ | -4.3224 |
| KIN | Kindred Biosciences Inc | $139.2M | NASDAQ | 20.6318 |
| KITE | Kite Pharma Inc | $3.7B | NASDAQ | 23.0576 |
| KTOV | Kitov Pharmaceuticals Holdings Ltd (ADR) | $13.2M | NASDAQ | |
| KURA | Kura Oncology Inc | $192.5M | NASDAQ | 8.9284 |
| LJPC | La Jolla Pharmaceutical Company | $626.6M | NASDAQ | 27.5126 |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.7B | NASDAQ | 0.0984 |
| LPCN | Lipocine Inc | $66.6M | NASDAQ | 25.8008 |
| LOXO | Loxo Oncology Inc | $938.7M | NASDAQ | 36.9068 |
| MGNX | MacroGenics Inc | $672.4M | NASDAQ | 9.4552 |
| MDGL | Madrigal Pharmaceuticals Inc | $180.3M | NASDAQ | 21.0343 |
| MNKD | MannKind Corporation | $99.4M | NASDAQ | -34.1407 |
| MNOV | MediciNova, Inc. | $188.9M | NASDAQ | 10.5449 |
| MDVN | Medivation Inc | $13.5B | NASDAQ | 15.6498 |
| MEIP | MEI Pharma Inc | $56.0M | NASDAQ | 1.8951 |
| MRUS | Merus NV | $293.6M | NASDAQ | 3.6125 |
| STEM | Microbot Medical Inc | $34.9M | NASDAQ | 13.3709 |
| MTP | Midatech Pharma PLC-ADR | $45.8M | NASDAQ | |
| NERV | Minerva Neurosciences Inc | $261.1M | NASDAQ | 5.0805 |
| MYOK | Myokardia Inc | $378.3M | NASDAQ | 4.6239 |
| NBRV | Nabriva Therapeutics AG - ADR | $20.5M | NASDAQ | 2.9177 |
| NNVC | NanoViricides Inc | $70.7M | NYSE MKT | 1.2228 |
| NK | Nantkwest Inc | $327.6M | NASDAQ | 7.1839 |
| NBIX | Neurocrine Biosciences, Inc. | $4.7B | NASDAQ | 52.5058 |
| NDRM | Neuroderm Ltd | $512.0M | NASDAQ | 46.9633 |
| NVET | Nexvet Biopharma plc | $78.8M | NASDAQ | 8.5051 |
| NVLS | Nivalis Therapeutics Inc | $37.3M | NASDAQ | 0.4356 |
| NVCR | Novocure Ltd | $1.0B | NASDAQ | 3.1337 |
| OMER | Omeros Corporation | $574.5M | NASDAQ | -5.0855 |
| OCX | OncoCyte Corp | $148.8M | NYSE MKT | 16.7674 |
| OPXA | Opexa Therapeutics Inc | $4.1M | NASDAQ | -54.6481 |
| OPHT | Ophthotech Corp | $91.0M | NASDAQ | -1.5708 |
| OREX | Orexigen Therapeutics, Inc. | $48.3M | NASDAQ | -2.1106 |
| OTIC | Otonomy Inc | $432.9M | NASDAQ | 15.6133 |
| PTIE | Pain Therapeutics, Inc. | $29.6M | NASDAQ | 17.0799 |
| PRTK | Paratek Pharmaceuticals Inc | $519.4M | NASDAQ | 1.9227 |
| PFNX | Pfenex Inc | $108.8M | NYSE MKT | 2.3821 |
| PIP | PharmAthene, Inc. | $44.7M | NYSE MKT | 0.0608 |
| PZRX | PhaseRx Inc | $14.5M | NASDAQ | -3.6643 |
| PIRS | Pieris Pharmaceuticals Inc | $163.6M | NASDAQ | 6.8735 |
| PGNX | Progenics Pharmaceuticals, Inc. | $502.5M | NASDAQ | 0.8885 |
| DNAI | ProNAi Therapeutics Inc | $41.9M | NASDAQ | -2.9808 |
| PRQR | ProQR Therapeutics NV | $119.1M | NASDAQ | 5.18 |
| PRTO | Proteon Therapeutics Inc | $24.1M | NASDAQ | -1.2605 |
| PTI | Proteostasis Therapeutics Inc | $112.2M | NASDAQ | 5.6981 |
| PRTA | Prothena Corporation PLC | $1.9B | NASDAQ | 12.0134 |
| PSDV | pSivida Corp. | $71.1M | NASDAQ | -7.9729 |
| PTCT | PTC Therapeutics, Inc. | $218.8M | NASDAQ | -0.2101 |
| PULM | Pulmatrix Inc | $47.9M | NASDAQ | -9.4129 |
| RDUS | Radius Health Inc | $1.5B | NASDAQ | 26.217 |
| RPTP | Raptor Pharmaceutical Corp. | $767.8M | NASDAQ | 1.074 |
| RETA | Reata Pharmaceuticals Inc | $168.8M | NASDAQ | -3.2875 |
| REPH | Recro Pharma Inc | $78.1M | NASDAQ | 0.7761 |
| REGN | Regeneron Pharmaceuticals Inc | $45.7B | NASDAQ | 12.2372 |
| RGNX | Regenxbio Inc | $489.7M | NASDAQ | 26.4137 |
| RLYP | Relypsa Inc | $1.4B | NASDAQ | 7.654 |
| RTRX | Retrophin Inc | $648.6M | NASDAQ | 2.3088 |
| RVNC | Revance Therapeutics Inc | $573.9M | NASDAQ | 10.7469 |
| RNN | Rexahn Pharmaceuticals, Inc. | $108.3M | NYSE MKT | 9.7152 |
| RIGL | Rigel Pharmaceuticals, Inc. | $265.1M | NASDAQ | -11.0436 |
| RTTR | Ritter Pharmaceuticals Inc | $5.3M | NASDAQ | -7.0924 |
| SGMO | Sangamo Therapeutics Inc | $589.9M | NASDAQ | 13.5585 |
| SRPT | Sarepta Therapeutics Inc | $1.9B | NASDAQ | 9.8549 |
| MSTX | Savara Inc | $33.1M | NYSE MKT | -21.3697 |
| SELB | Selecta Biosciences Inc | $245.7M | NASDAQ | 2.9893 |
| MCRB | Seres Therapeutics Inc | $403.1M | NASDAQ | 1.651 |
| SRNE | Sorrento Therapeutics Inc | $86.5M | NASDAQ | -0.3854 |
| ONCE | Spark Therapeutics Inc | $1.8B | NASDAQ | 24.2438 |
| SBPH | Spring Bank Pharmaceuticals Inc | $86.8M | NASDAQ | 3.5981 |
| STDY | Steadymed Ltd | $141.5M | NASDAQ | 2.4585 |
| STML | Stemline Therapeutics Inc | $206.7M | NASDAQ | 9.7985 |
| SCMP | Sucampo Pharmaceuticals, Inc. | $497.2M | NASDAQ | 2.0165 |
| SMMT | Summit Therapeutics PLC (ADR) | $134.1M | NASDAQ | |
| SGYP | Synergy Pharmaceuticals Inc | $777.0M | NASDAQ | 0.623 |
| SYN | Synthetic Biologics Inc | $60.6M | NYSE MKT | -8.6563 |
| TSRO | TESARO Inc | $7.5B | NASDAQ | 20.4417 |
| TBRA | Tobira Therapeutics Inc | $462.0M | NASDAQ | 9.77 |
| TCON | TRACON Pharmaceuticals Inc | $41.5M | NASDAQ | -0.1856 |
| TRVN | Trevena Inc | $184.5M | NASDAQ | 0.5596 |
| RARE | Ultragenyx Pharmaceutical Inc | $2.3B | NASDAQ | 19.9592 |
| QURE | Uniqure NV | $123.8M | NASDAQ | -1.4323 |
| VNDA | Vanda Pharmaceuticals Inc. | $627.6M | NASDAQ | 3.8559 |
| VBLT | Vascular Biogenics Ltd | $165.4M | NASDAQ | 16.8488 |
| VSTM | Verastem Inc | $90.6M | NASDAQ | 1.8685 |
| VSAR | Versartis Inc | $517.0M | NASDAQ | 4.6016 |
| VRTX | Vertex Pharmaceuticals Incorporated | $28.4B | NASDAQ | 8.2055 |
| VICL | Vical Incorporated | $25.0M | NASDAQ | -7.7749 |
| VTL | Vital Therapies Inc | $97.8M | NASDAQ | 6.231 |
| VTVT | vTv Therapeutics Inc | $171.6M | NASDAQ | -3.9211 |
| XBIT | XBiotech Inc | $313.7M | NASDAQ | 20.2473 |
| XNCR | Xencor Inc | $913.6M | NASDAQ | 4.3066 |
| XENE | Xenon Pharmaceuticals Inc | $75.6M | NASDAQ | 10.8068 |
| XOMA | XOMA Corp | $37.7M | NASDAQ | -19.5052 |
| ZFGN | Zafgen Inc | $112.9M | NASDAQ | 5.424 |
| ZIOP | ZIOPHARM Oncology Inc. | $969.5M | NASDAQ | 2.3798 |
| ZSAN | Zosano Pharma Corp | $47.7M | NASDAQ | -11.1189 |